Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Target Recruit Count
- 42
- Registration Number
- NCT06439550
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06439693
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06435429
- Locations
- 🇺🇸
USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Washington Cancer Center, Washington, District of Columbia, United States
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Target Recruit Count
- 312
- Registration Number
- NCT06278870
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Iambic Therapeutics, Inc
- Target Recruit Count
- 287
- Registration Number
- NCT06253871
- Locations
- 🇺🇸
Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 73
- Registration Number
- NCT06245356
- Locations
- 🇫🇷
Institut du Cancer d'Avignon, Avignon, France
🇫🇷CHU Jean Minjoz, Besançon, France
🇫🇷Centre Hospitalier de Cholet, Cholet, France
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06239467
- Locations
- 🇺🇸
SCRI Oncology Partners - Nashville, Nashville, Tennessee, United States
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇫🇷Centre Antoine Lacassagne, Nice, France
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06217185
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06162559
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.